Overview
Spherix’s coverage of the psoriatic arthritis market provides a full-picture analysis of the current PsA market landscape in the US and EU5, as well as perceptions and uptake of new entrants. Insights serve to bolster understanding of the market and provide input for brand commercialization plans.
Services Available
Trending market evolution
Psoriatic Arthritis (US) - quarterly, n=100
Psoriatic Arthritis (EU) - semiannual, n=250
Exploring the patient journey
Biologic/Small Molecule Switching in Psoriatic Arthritis (US) - n=1,000 patient charts
Biologic/Small Molecule Switching in PsA – Dermatology Perspective (US) - n=500 patient charts
Benchmarking new brand performance
Tremfya (Janssen) in Psoriatic Arthritis (US)
Rinvoq (AbbVie) in Psoriatic Arthritis (US)*
Skyrizi (AbbVie) in Psoriatic Arthritis*
*Pending approvals and launch
Gauging impact of disruptive events
Multi-Specialty Impact of COVID-19 (US)